JEVTANA- cabazitaxel kit United States - English - NLM (National Library of Medicine)

jevtana- cabazitaxel kit

sanofi-aventis u.s. llc - cabazitaxel (unii: 51f690397j) (cabazitaxel - unii:51f690397j) - cabazitaxel 60 mg in 1.5 ml - jevtana® is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. jevtana is contraindicated in patients with: - neutrophil counts of ≤1,500/mm3 [see warnings and precautions (5.1)] - history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80 [see warnings and precautions (5.3)] - severe hepatic impairment (total bilirubin >3 × uln) [see warnings and precautions (5.8)] risk summary the safety and efficacy of jevtana have not been established in females. there are no human data on the use of jevtana in pregnant women to inform the drug-associated risk. in animal reproduction studies, intravenous administration of cabazitaxel in pregnant rats during organogenesis caused embryonic and fetal death at doses lower than the maximum recommended human dose [see data] . data animal data in an early embryonic developmental toxicity stu

Cabazitaxel Teva 10 mg/ml inf. sol. (conc.) i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cabazitaxel teva 10 mg/ml inf. sol. (conc.) i.v. vial

teva b.v. - cabazitaxel ethyl acetate 11,05 mg/ml - eq. cabazitaxel 10 mg/ml - concentrate for solution for infusion - 10 mg/ml - cabazitaxel ethylacetate 11.05 mg/ml - cabazitaxel

Cabazitaxel Mylan 60 mg i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cabazitaxel mylan 60 mg i.v. vial

viatris gx bv-srl - cabazitaxel 40 mg/ml - concentrate and diluent for solution for infusion - 60 mg - cabazitaxel 40 mg/ml - cabazitaxel

Cabazitaxel Ever Pharma 10 mg/ml inf. sol. (conc.) i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cabazitaxel ever pharma 10 mg/ml inf. sol. (conc.) i.v. vial

ever valinject gmbh - cabazitaxel ethyl acetate 45 mg - concentrate for solution for infusion - 10 mg/ml - cabazitaxel 10 mg/ml - cabazitaxel

Cabazitaxel Ever Pharma 10 mg/ml inf. sol. (conc.) i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cabazitaxel ever pharma 10 mg/ml inf. sol. (conc.) i.v. vial

ever valinject gmbh - cabazitaxel ethyl acetate 45 mg - concentrate for solution for infusion - 10 mg/ml - cabazitaxel 10 mg/ml - cabazitaxel

Cabazitaxel Ever Pharma 10 mg/ml inf. sol. (conc.) i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cabazitaxel ever pharma 10 mg/ml inf. sol. (conc.) i.v. vial

ever valinject gmbh - cabazitaxel ethyl acetate 45 mg - concentrate for solution for infusion - 10 mg/ml - cabazitaxel 10 mg/ml - cabazitaxel

Cabazitaxel Viatris 20 mg/ml inf. sol. (conc.) i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cabazitaxel viatris 20 mg/ml inf. sol. (conc.) i.v. vial

viatris gx bv-srl - cabazitaxel 20 mg/ml - concentrate for solution for infusion - 20 mg/ml - cabazitaxel 20 mg/ml - cabazitaxel

CABAZITAXEL EVER PHARMA 10 MGML Israel - English - Ministry of Health

cabazitaxel ever pharma 10 mgml

pharmalogic ltd - cabazitaxel - concentrate for solution for infusion - cabazitaxel 10 mg / 1 ml - cabazitaxel - cabazitaxel is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel- containing treatment regimen.

Cabazitaxel Fresenius Kabi 20 mg/ml concentrate for solution for infusion Malta - English - Medicines Authority

cabazitaxel fresenius kabi 20 mg/ml concentrate for solution for infusion

fresenius kabi italia s.r.l via camagre 41, 37063 isola della scala (vr) , italy - concentrate for solution for infusion - cabazitaxel 20 mg/ml - antineoplastic agents

JEVTANA cabazitaxel 60 mg/1.5 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

jevtana cabazitaxel 60 mg/1.5 ml concentrated injection vial

sanofi-aventis australia pty ltd - cabazitaxel acetone solvate, quantity: 64.17 mg - diluent, not applicable - excipient ingredients: water for injections; ethanol - jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.